Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 228 followers
Latest posts
Last updated 3 days ago
New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis
3 days ago
Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to...
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
4 days ago
Japan is the second major market where Kisunla has received approval Kisunla...
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
14 days ago
EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that...
Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
16 days ago
Company ups manufacturing investment in Limerick by $1 billion ; unveils new...
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
17 days ago
Detailed results were published in The Lancet and simultaneously presented at the...
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
17 days ago
In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and...
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
19 days ago
INDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE...
In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
23 days ago
In the phase 3 study, QWINT-1, efsitora was administered via four fixed...
Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
24 days ago
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to...
Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
about 1 month ago
Distributed through LillyDirect ® 's self-pay channel, Zepbound single-dose vials are at...
Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference
about 1 month ago
INDIANAPOLIS , Aug. 22, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
about 1 month ago
176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest...